AR3

CYTARABINE

Created:	2003-04-29
Last modified:	2020-06-05

Find Related PDB Entry
2 entries where AR3 is found as a standalone ligand

Help Find related ligands:
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Help

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	30
Chiral Atom Count	4
Bond Count	31
Aromatic Bond Count	6

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	CYTARABINE
Synonyms	1-BETA-D-ARABINOFURANOSYLCYTOSINE; ARA-C
Systematic Name (OpenEye OEToolkits)	4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
Formula	C₉ H₁₃ N₃ O₅
Molecular Weight	243.217
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	10.04	O=C1N=C(N)C=CN1C2OC(C(O)C2O)CO
SMILES	CACTVS	3.341	NC1=NC(=O)N(C=C1)[CH]2O[CH](CO)[CH](O)[CH]2O
SMILES	OpenEye OEToolkits	1.5.0	C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O
Canonical SMILES	CACTVS	3.341	NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O
Canonical SMILES	OpenEye OEToolkits	1.5.0	C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
InChI	InChI	1.03	InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
InChIKey	InChI	1.03	UHDGCWIWMRVCDJ-CCXZUQQUSA-N

Drug Info: DrugBank

DrugBank ID	DB00987
Name	Cytarabine
Groups	approved investigational
Description	A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Synonyms	Citarabina 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone Cytosine arabinoside Cytarabine liposome Cytarabine 1-beta-D-Arabinofuranosylcytosine cytosine-β-D-arabinofuranoside Cytarabinum Cytosine-1-beta-D-arabinofuranoside Cytarabine hydrochloride
Brand Names	Cytarabine Vyxeos Liposomal Aj-cytarabine Cytarabine Injection, Mylan Std. Cytarabine Injection BP Cytarabine - Pws 2gm/vial Cytosar DepoCyt Cytarabine Inj 100mg/ml Cytarabine Injection Cytarabine-pws 100mg/vial Depocyte PMS-cytarabine Vyxeos Cytarabine - Pws 500mg/vial Cytarabine - Pws 1gn/vial
Indication	For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia. Cytarabine is indicated in combination with [daunorubicin] for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.[L32843]
Categories	Agents Causing Muscle Toxicity Anti-Infective Agents Antimetabolites Antineoplastic Agents Antineoplastic and Immunomodulating Agents Arabinonucleosides Cardiotoxic antineoplastic agents Cytidine Deaminase Substrates Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index Cytochrome P-450 Substrates Immunologic Factors Immunosuppressive Agents Myelosuppressive Agents Narrow Therapeutic Index Drugs Noxae Nucleic Acid Synthesis Inhibitors Nucleic Acids, Nucleotides, and Nucleosides Nucleoside Metabolic Inhibitor Nucleosides OCT1 substrates Pyrimidine Analogues Pyrimidine Nucleosides Pyrimidines Toxic Actions
ATC-Code	L01BC01 L01XY01
CAS number	147-94-4

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
DNA polymerase beta	MSKRKAPQETLNGGITDMLTELANFEKNVSQAIHKYNAYRKAASVIAKYP...	unknown	inhibitor
DNA	-	unknown	cross-linking/alkylation
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate
Deoxycytidine kinase	MATPPKRSCPSFSASSEGTRIKKISIEGNIAAGKSTFVNILKQLCEDWEV...	unknown	substrate
5'-nucleotidase	MCPRAARAPATLLLALGAVLWPAAGAWELTILHTNDVHSRLEQTSEDSSK...	unknown	substrate
Deoxycytidylate deaminase	MSEVSCKKRDDYLEWPEYFMAVAFLSAQRSKDPNSQVGACIVNSENKIVG...	unknown	substrate
Cytidine deaminase	MAQKRPACTLKPECVQQLLVCSQEAKKSAYCPYSHFPVGAALLTQEGRIF...	unknown	substrate
Solute carrier family 22 member 4	MRDYDEVIAFLGEWGPFQRLIFFLLSASIIPNGFNGMSVVFLAGTPEHRC...	unknown	substrate
Multidrug resistance-associated protein 7	MERLLAQLCGSSAAWPLPLWEGDTTGHCFTQLVLSALPHALLAVLSACYL...	unknown	substrate
Equilibrative nucleoside transporter 1	MTTSHQPQDRYKAVWLIFFMLGLGTLLPWNFFMTATQYFTNRLDMSQNVS...	unknown	substrate
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682